UBS maintains Clover Health Investments at Neutral, raises price target to $5.50 from $5
UBS kept its Neutral rating on Clover Health Investments but raised its price target to $5.50 from $5, a 10% increase. This implies a 22.8% upside from the Nov 5 close of $4.48, according to the firm.
How this was made

The 30-second read
Why it matters
The upgrade may prompt short‑term buying, but overall market reaction is expected to be modest.
Market read
A modest analyst upgrade with a new price target, offering limited trading opportunity.
What to watch
Potential regulatory risks and competition in the Medicare Advantage space.
Background
UBS issued a neutral rating with a higher price target for Clover Health Investments.
Ticker impact
UBS raised its price target on Clover Health Investments to $5.50 from $5, indicating potential upside.
likely modest upside as investors price in the higher target
The new target suggests a 22.8% upside from the recent close, which could attract interest.
Market effects
May slightly lift other health‑tech stocks as analysts reassess valuations.
Limited to U.S. market participants focused on health‑tech.
Minimal global impact.
Counterpoint
The target raise could be premature if the company's growth outlook remains uncertain.
Key entities
- companyClover Health Investments
U.S. health‑tech firm providing Medicare Advantage plans.
- analystUBS
Investment bank providing the rating and target.


